Skip to content
10-Q

Quarterly Report

Dianthus Therapeutics, Inc. DNTH

0000950170-25-069226

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 32.16M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $253.11M
Short Term Investments Q1 2025 · Dec 31, 2024 $252.45M
Current Liabilities Q1 2025 · Mar 31, 2025 $16.95M
Current Liabilities Q1 2025 · Dec 31, 2024 $18.45M
Total Liabilities Q1 2025 · Mar 31, 2025 $19.97M
Total Liabilities Q1 2025 · Dec 31, 2024 $21.53M
Current Assets Q1 2025 · Mar 31, 2025 $271M
Current Assets Q1 2025 · Dec 31, 2024 $280.9M
Total Assets Q1 2025 · Mar 31, 2025 $348.58M
Total Assets Q1 2025 · Dec 31, 2024 $374.01M
Revenue Q1 2025 · Mar 31, 2025 $1.16M
Revenue Q1 2025 · Mar 31, 2024 $874K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $22.79M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $329.72M
Shares Diluted Q1 2025 · Mar 31, 2024 25.67M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$14.94M
Stockholders Equity Q1 2025 · Mar 31, 2024 $372.69M
Stockholders Equity Q1 2025 · Dec 31, 2023 $168.87M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.54
Eps Basic Q1 2025 · Mar 31, 2024 −$0.54
Sga Expense Q1 2025 · Mar 31, 2024 $5.64M
Rd Expense Q1 2025 · Mar 31, 2024 $13.08M
Net Income Q1 2025 · Mar 31, 2024 −$13.75M
Operating Income Q1 2025 · Mar 31, 2024 −$17.84M